-
Oppenheimer on Coherus Biosciences (CHRS): 'We see potential for CHRS shares to build on recent gains'
-
Oppenheimer Starts Coherus Biosciences (CHRS) at Outperform
-
Coherus announces publication of CCR8 antibody tagmokitug research data
-
Coherus reports extended survival data for LOQTORZI cancer treatment
-
Coherus presents data on CHS-114 cancer drug at SITC conference
-
Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
-
Coherus Oncology names Arvind Sood as chief strategy officer
-
Maxim Group Upgrades Coherus Biosciences (CHRS) to Buy, PT $4
-
Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
-
Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
-
H.C. Wainwright Reiterates Buy Rating on Coherus Biosciences (CHRS)
-
Coherus BioSciences (CHRS) announces promising data from CHS-114 trial
-
Coherus BioSciences (CHRS) Announces Repurchase of Approximately $170M of Convertible Notes
-
H.C. Wainwright Upgrades Coherus Biosciences (CHRS) to Buy
-
Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
-
Coherus Biosciences (CHRS) PT Raised to $6 at Baird
-
Coherus Biosciences (CHRS) PT Lowered to $7 at H.C. Wainwright
-
Coherus BioSciences (CHRS) Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
-
Citi Out Positive on Coherus Biosciences (CHRS): 'Erasing the $230M convert debt due in 2026 extinguishes a much-debated overhang'
-
Coherus BioSciences (CHRS) Tops Q3 EPS by 15c
-
TD Cowen Reiterates Buy Rating on Coherus Biosciences (CHRS)
-
Baird Reiterates Outperform Rating on Coherus Biosciences (CHRS)
-
UBS Downgrades Coherus Biosciences (CHRS) to Neutral
-
Coherus BioSciences (CHRS) Tops Q2 EPS by 11c ; Offers Guidance
-
Coherus Biosciences (CHRS) PT Lowered to $8 at Baird
-
Coherus BioSciences (CHRS) to Sell YUSIMRY for $40M Cash

